D. Dickinson Andrew's Insider Trades & SAST Disclosures
D. Dickinson Andrew's most recent trade in Gilead Sciences, Inc. was a trade of 2,500 Common Stock done at an average price of $99.8 . Disclosure was reported to the exchange on May 15, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern D. Dickinson Andrew.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 99.82 per share. | 15 May 2025 | 2,500 | 165,674 (0%) | 0% | 99.8 | 249,550 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 106.40 per share. | 15 Apr 2025 | 2,500 | 168,174 (0%) | 0% | 106.4 | 266,000 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 110.53 per share. | 17 Mar 2025 | 2,500 | 170,674 (0%) | 0% | 110.5 | 276,325 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 49,020 | 49,020 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.91 per share. | 10 Mar 2025 | 13,013 | 186,990 (0%) | 0% | 63.9 | 831,661 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 118.50 per share. | 10 Mar 2025 | 13,013 | 169,061 (0%) | 0% | 118.5 | 1,542,055 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 13,013 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 11,090 | 38,609 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 7,968 | 177,029 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 7,968 | 27,519 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.91 per share. | 10 Mar 2025 | 4,916 | 173,977 (0%) | 0% | 63.9 | 314,182 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 117.30 per share. | 10 Mar 2025 | 4,916 | 182,074 (0%) | 0% | 117.3 | 576,641 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 4,916 | 13,013 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.21 per share. | 10 Mar 2025 | 3,855 | 173,174 (0%) | 0% | 117.2 | 451,845 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 104.09 per share. | 18 Feb 2025 | 2,500 | 169,061 (0%) | 0% | 104.1 | 260,225 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 102.22 per share. | 12 Feb 2025 | 137,676 | 171,223 (0%) | 0% | 102.2 | 14,073,241 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 77,691 | 17,929 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.91 per share. | 12 Feb 2025 | 77,691 | 248,914 (0%) | 0% | 63.9 | 4,965,232 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.92 per share. | 12 Feb 2025 | 26,175 | 275,089 (0%) | 0% | 57.9 | 1,516,056 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 26,175 | 78,515 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 18,210 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 83.49 per share. | 12 Feb 2025 | 18,210 | 308,899 (0%) | 0% | 83.5 | 1,520,353 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 15,600 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 80.72 per share. | 12 Feb 2025 | 15,600 | 290,689 (0%) | 0% | 80.7 | 1,259,232 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 64,695 | 214,361 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 97.99 per share. | 04 Feb 2025 | 43,138 | 171,223 (0%) | 0% | 98.0 | 4,227,093 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 19,793 | 149,666 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 97.22 per share. | 31 Jan 2025 | 142,180 | 129,873 (0%) | 0% | 97.2 | 13,822,740 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 71,850 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.34 per share. | 31 Jan 2025 | 71,850 | 227,893 (0%) | 0% | 72.3 | 5,197,629 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 44,160 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 65.38 per share. | 31 Jan 2025 | 44,160 | 273,053 (0%) | 0% | 65.4 | 2,887,181 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 26,170 | 104,690 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.92 per share. | 31 Jan 2025 | 26,170 | 156,043 (0%) | 0% | 57.9 | 1,515,766 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 91.35 per share. | 15 Jan 2025 | 2,500 | 129,873 (0%) | 0% | 91.4 | 228,375 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 91.96 per share. | 16 Dec 2024 | 8,500 | 132,373 (0%) | 0% | 92.0 | 781,660 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 3,640 | 142,559 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 3,640 | 35,487 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.34 per share. | 10 Dec 2024 | 1,686 | 140,873 (0%) | 0% | 92.3 | 155,685 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 92.76 per share. | 29 Nov 2024 | 127,930 | 138,919 (0%) | 0% | 92.8 | 11,867,119 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 92.77 per share. | 29 Nov 2024 | 120,715 | 266,849 (0%) | 0% | 92.8 | 11,198,151 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2024 | 65,960 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.70 per share. | 29 Nov 2024 | 65,960 | 387,564 (0%) | 0% | 72.7 | 4,795,292 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2024 | 60,885 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 71.91 per share. | 29 Nov 2024 | 60,885 | 278,264 (0%) | 0% | 71.9 | 4,378,240 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2024 | 43,340 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.70 per share. | 29 Nov 2024 | 43,340 | 321,604 (0%) | 0% | 72.7 | 3,150,818 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2024 | 33,660 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 68.75 per share. | 29 Nov 2024 | 33,660 | 217,379 (0%) | 0% | 68.8 | 2,314,125 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2024 | 26,170 | 130,860 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.92 per share. | 29 Nov 2024 | 26,170 | 183,719 (0%) | 0% | 57.9 | 1,515,766 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2024 | 18,630 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 73.77 per share. | 29 Nov 2024 | 18,630 | 157,549 (0%) | 0% | 73.8 | 1,374,335 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 3,641 | 140,601 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 3,641 | 39,127 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.44 per share. | 10 Sep 2024 | 1,682 | 138,919 (0%) | 0% | 81.4 | 136,982 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 3,639 | 138,622 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 3,639 | 42,768 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.25 per share. | 10 Jun 2024 | 1,662 | 136,960 (0%) | 0% | 65.3 | 108,446 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 87,970 | 87,970 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 17,305 | 46,407 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 6,707 | 139,488 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 6,707 | 28,333 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.12 per share. | 10 Mar 2024 | 4,505 | 134,983 (0%) | 0% | 75.1 | 338,416 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 3,025 | 132,781 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 3,025 | 35,040 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Dickinson Andrew D. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 55,955 | 152,846 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | D. Andrew Dickinson | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.26 per share. | 31 Jan 2024 | 23,410 | 129,436 (0%) | 0% | 78.3 | 1,832,067 | Common Stock |
| Gilead Sciences, Inc. | D. Andrew Dickinson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 19,006 | 96,891 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Dickinson D. Andrew | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 85.78 per share. | 16 Jan 2024 | 5,000 | 101,534 (0%) | 0% | 85.8 | 428,900 | Common Stock |
| Gilead Sciences, Inc. | Dickinson Andrew D. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2023 | 2,617 | 38,834 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Dickinson D. Andrew | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2023 | 2,617 | 107,728 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Andrew Dickinson D. | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.02 per share. | 10 Dec 2023 | 1,194 | 106,534 (0%) | 0% | 79.0 | 94,350 | Common Stock |
| Gilead Sciences, Inc. | Dickinson Andrew D. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2023 | 1,912 | 105,915 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | D. Dickinson Andrew | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2023 | 1,912 | 41,451 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | D. Andrew Dickinson | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.92 per share. | 10 Nov 2023 | 804 | 105,111 (0%) | 0% | 75.9 | 61,040 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 80.00 per share. | 17 Oct 2023 | 5,000 | 104,003 (0%) | 0% | 80.0 | 400,017 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2023 | 2,619 | 110,206 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2023 | 2,619 | 43,363 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 76.00 per share. | 10 Sep 2023 | 1,203 | 109,003 (0%) | 0% | 76 | 91,428 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 80.00 per share. | 20 Jul 2023 | 5,000 | 107,587 (0%) | 0% | 80 | 400,000 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2023 | 2,618 | 74,920 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2023 | 2,618 | 45,982 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.12 per share. | 10 Jun 2023 | 1,219 | 73,701 (0%) | 0% | 78.1 | 95,228 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 74,565 | 74,565 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 16,350 | 48,600 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 7,394 | 116,037 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 7,394 | 32,250 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.50 per share. | 10 Mar 2023 | 4,849 | 111,188 (0%) | 0% | 79.5 | 385,496 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 3,025 | 108,643 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 3,025 | 39,644 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 56.38 per share. | 15 Feb 2023 | 376 | 105,618 (0%) | 0% | 56.4 | 21,199 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2023 | 1,817 | 105,773 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2023 | 1,817 | 42,669 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.36 per share. | 06 Feb 2023 | 531 | 105,242 (0%) | 0% | 86.4 | 45,857 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2023 | 38,270 | 119,283 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2023 | 27,932 | 81,013 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.02 per share. | 24 Jan 2023 | 15,327 | 103,956 (0%) | 0% | 84.0 | 1,287,775 | Common Stock |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2022 | 1,027 | 69,695 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2022 | 1,027 | 44,486 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Andrew D. Dickinson | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.97 per share. | 10 Dec 2022 | 480 | 69,215 (0%) | 0% | 88.0 | 42,226 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges